Skip to main content
Livermore
Livermore
ZHEN

Deep Track Capital, LP

SEC CIK
0001856083
Latest filing
Aug 14, 2026

Holdings in Q1 2026

Holdings as of Mar 31, 2026, filed May 15, 2026. Long positions only; changes compare share counts with Q4 2025.

Institution overview
Positions
62
+9 vs. Q4 2025
Portfolio value
$4.85B
+$462.5M (+10.5%) vs. Q4 2025
Filed
May 15, 2026
SEC
Holdings of Deep Track Capital, LP in Q1 2026
SecurityClassSharesValue% of portfolioShare changeActionHistory
GHGuardant Health, Inc.COM3,338,241$308.4M6.4%+538,241+19.2%AddedHistory
IMVTImmunovant, Inc.COM11,526,971$286.3M5.9%00.0%UnchangedHistory
TARSTarsus Pharmaceuticals, Inc.COM3,600,000$252.5M5.2%+595,966+19.8%AddedHistory
PCVXVaxcyte, Inc.COM4,300,000$249.9M5.2%+300,000+7.5%AddedHistory
GPCRStructure Therapeutics Inc.SPONSORED ADS4,279,848$206.3M4.3%+168,066+4.1%AddedHistory
AXSMAxsome Therapeutics, Inc.COM1,100,000$185.9M3.8%−50,000−4.3%ReducedHistory
APLSApellis Pharmaceuticals, Inc.COM4,532,374$182.3M3.8%−3,217,626−41.5%ReducedHistory
OCULOcular Therapeutix, IncCOM19,686,282$166.7M3.4%+11,615,868+143.9%AddedHistory
VERAVera Therapeutics, Inc.CL A4,106,067$165.2M3.4%+1,284,932+45.5%AddedHistory
ALMSAlumis Inc.COM6,772,595$149.2M3.1%+6,772,595NewHistory
IONSIonis Pharmaceuticals IncCOM1,950,000$146.4M3.0%+250,000+14.7%AddedHistory
NUVLNuvalent, Inc.COM1,376,324$141.0M2.9%+1,376,324NewHistory
ALKSAlkermes plc.SHS3,590,323$127.0M2.6%+1,590,323+79.5%AddedHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS3,158,041$125.4M2.6%+1,158,041+57.9%AddedHistory
MLTXMoonLake ImmunotherapeuticsCLASS A ORD6,408,863$119.5M2.5%+1,798,792+39.0%AddedHistory
MAZEMaze Therapeutics, Inc.COM3,477,562$103.8M2.1%−768,878−18.1%ReducedHistory
ORKAOruka Therapeutics, Inc.COM2,034,203$99.8M2.1%−127,307−5.9%ReducedHistory
NRIXNurix Therapeutics, Inc.COM6,345,244$98.4M2.0%−691,211−9.8%ReducedHistory
GMABGenmab A/SSPONSORED ADS3,663,250$98.3M2.0%+3,663,250NewHistory
CYTKCytokinetics IncCOM NEW1,374,320$90.6M1.9%−1,962,678−58.8%ReducedHistory
GRALGRAIL, Inc.COM1,722,797$89.0M1.8%+700,000+68.4%AddedHistory
LBRXLB Pharmaceuticals IncCOM SHS3,352,804$82.7M1.7%00.0%UnchangedHistory
MBXMBX Biosciences, Inc.COM2,757,569$82.3M1.7%−492,221−15.1%ReducedHistory
BCAXBicara Therapeutics Inc.COM4,062,500$80.8M1.7%+1,448,496+55.4%AddedHistory
CMPSCOMPASS Pathways plcSPONSORED ADS12,161,496$67.3M1.4%+4,827,173+65.8%AddedHistory
BMRNBiomarin Pharmaceutical IncCOM1,150,000$65.0M1.3%−1,150,000−50.0%ReducedHistory
BBIOBridgeBio Pharma, Inc.COM841,445$62.5M1.3%+31,303+3.9%AddedHistory
IMCRImmunocore Holdings plcADS1,931,884$58.2M1.2%−72,094−3.6%ReducedHistory
TNGXTango Therapeutics, Inc.COM2,750,000$57.5M1.2%+295,438+12.0%AddedHistory
DFTXDefinium Therapeutics, Inc.COM SHS3,000,000$56.7M1.2%+1,323,460+78.9%AddedHistory
TERNTerns Pharmaceuticals, Inc.COM1,073,877$56.6M1.2%+304,829+39.6%AddedHistory
GERNGeron CorpCOM31,720,278$47.3M1.0%−790,993−2.4%ReducedHistory
ANIPAni Pharmaceuticals IncCOM600,000$46.1M1.0%+122,316+25.6%AddedHistory
CRMDCorMedix Inc.COM6,274,076$42.6M0.9%+1,000,000+19.0%AddedHistory
ATAIAtaiBeckley Inc.COM SHS12,000,000$42.5M0.9%+7,322,711+156.6%AddedHistory
CLDXCelldex Therapeutics, Inc.COM NEW1,283,979$40.7M0.8%−616,759−32.4%ReducedHistory
COGTCogent Biosciences, Inc.COM1,000,000$38.5M0.8%+546,898+120.7%AddedHistory
CRVSCorvus Pharmaceuticals, Inc.COM2,491,539$36.5M0.8%+2,491,539NewHistory
DYNDyne Therapeutics, Inc.COM2,000,000$36.3M0.7%−650,000−24.5%ReducedHistory
SLNOSoleno Therapeutics IncCOM1,078,710$36.1M0.7%+78,710+7.9%AddedHistory
ACRSAclaris Therapeutics, Inc.COM9,345,000$35.0M0.7%+9,345,000NewHistory
MANEVeradermics, IncCOMMON STOCK500,000$31.6M0.7%+500,000NewHistory
VSTMVerastem, Inc.COM NEW5,740,850$30.4M0.6%00.0%UnchangedHistory
ENGNenGene Therapeutics Inc.COM4,377,572$29.8M0.6%00.0%UnchangedHistory
VRDNViridian Therapeutics, Inc.COM1,393,944$27.3M0.6%−1,130,889−44.8%ReducedHistory
XFORX4 Pharmaceuticals, IncCOM NEW6,339,535$26.2M0.5%+1,325,874+26.4%AddedHistory
SLDBSolid Biosciences Inc.COM NEW3,565,062$25.7M0.5%+3,565,062NewHistory
ENTAEnanta Pharmaceuticals IncCOM1,956,867$24.7M0.5%00.0%UnchangedHistory
APGEApogee Therapeutics, Inc.COM285,000$24.0M0.5%+285,000NewHistory
KURAKura Oncology, Inc.COM2,643,542$21.5M0.4%+2,643,542NewHistory
IPSCCentury Therapeutics, Inc.COM9,487,745$21.4M0.4%+9,487,745NewHistory
BEAMBeam Therapeutics Inc.COM820,765$19.6M0.4%+820,765NewHistory
CNTXContext Therapeutics Inc.COM7,419,355$19.4M0.4%00.0%UnchangedHistory
PSNLPersonalis, Inc.COM3,000,000$19.1M0.4%+3,000,000NewHistory
JANXJanux Therapeutics, Inc.COM1,187,290$16.5M0.3%+1,097,701+1,225.3%AddedHistory
PMNProMIS Neurosciences Inc.COM SHS835,655$10.6M0.2%+835,655NewHistory
CBIOCrescent Biopharma, Inc.COM453,686$8.33M0.2%00.0%UnchangedHistory
IVAInventiva S.A.ADS1,222,453$6.78M0.1%+732,453+149.5%AddedHistory
LRMRLarimar Therapeutics, Inc.COM1,500,000$6.75M0.1%+1,500,000NewHistory
HELPCybin Inc.COM NEW1,313,137$6.30M0.1%−541,118−29.2%ReducedHistory
BLLNBillionToOne, Inc.CL A50,000$3.95M0.1%00.0%UnchangedHistory
ALGSAligos Therapeutics, Inc.COM NEW444,110$3.30M0.1%00.0%UnchangedHistory

Options (1)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Deep Track Capital, LP in Q1 2026
SecurityClassPutsCalls
State Street SPDR S&P Biotech ETF78464A870ETF$1.28B–

Sold out since Q4 2025 (5)

Positions held at the end of Q4 2025 that are gone from this filing.

Positions of Deep Track Capital, LP sold out since Q4 2025
SecurityClassShares in Q4 2025Value in Q4 2025% of portfolio in Q4 2025History
DVAXDynavax Technologies CorpCOM NEW15,726,349$241.9M5.5%History
XENEXenon Pharmaceuticals Inc.COM366,435$16.4M0.4%History
MNPRMonopar TherapeuticsCOM NEW95,408$6.23M0.1%History
RAPTRAPT Therapeutics, Inc.COM NEW110,448$3.74M0.1%History
ANLAdlai Nortye Group Ltd.ADS34,852$49.5K<0.1%History